JP2014520786A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520786A5
JP2014520786A5 JP2014517820A JP2014517820A JP2014520786A5 JP 2014520786 A5 JP2014520786 A5 JP 2014520786A5 JP 2014517820 A JP2014517820 A JP 2014517820A JP 2014517820 A JP2014517820 A JP 2014517820A JP 2014520786 A5 JP2014520786 A5 JP 2014520786A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517820A
Other languages
English (en)
Japanese (ja)
Other versions
JP6101260B2 (ja
JP2014520786A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063242 external-priority patent/WO2013004816A1/en
Publication of JP2014520786A publication Critical patent/JP2014520786A/ja
Publication of JP2014520786A5 publication Critical patent/JP2014520786A5/ja
Application granted granted Critical
Publication of JP6101260B2 publication Critical patent/JP6101260B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517820A 2011-07-07 2012-07-06 ダルナビル製剤 Active JP6101260B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173066.9 2011-07-07
EP11173066 2011-07-07
PCT/EP2012/063242 WO2013004816A1 (en) 2011-07-07 2012-07-06 Darunavir formulations

Publications (3)

Publication Number Publication Date
JP2014520786A JP2014520786A (ja) 2014-08-25
JP2014520786A5 true JP2014520786A5 (enExample) 2015-07-16
JP6101260B2 JP6101260B2 (ja) 2017-03-22

Family

ID=46458539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517820A Active JP6101260B2 (ja) 2011-07-07 2012-07-06 ダルナビル製剤

Country Status (23)

Country Link
US (3) US20140142174A1 (enExample)
EP (1) EP2729128B1 (enExample)
JP (1) JP6101260B2 (enExample)
KR (1) KR101817991B1 (enExample)
CN (1) CN103841962B (enExample)
AU (1) AU2012280277B2 (enExample)
BR (1) BR112014000195A2 (enExample)
CA (1) CA2837539C (enExample)
CY (1) CY1119446T1 (enExample)
DK (1) DK2729128T3 (enExample)
EA (1) EA026588B1 (enExample)
ES (1) ES2598823T3 (enExample)
HR (1) HRP20161340T1 (enExample)
HU (1) HUE030341T2 (enExample)
IL (1) IL229700B (enExample)
LT (1) LT2729128T (enExample)
MX (1) MX341976B (enExample)
PL (1) PL2729128T3 (enExample)
PT (1) PT2729128T (enExample)
RS (1) RS55236B1 (enExample)
SI (1) SI2729128T1 (enExample)
SM (1) SMT201600380B (enExample)
WO (1) WO2013004816A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140142070A1 (en) 2011-07-07 2014-05-22 Janssen R&D Ireland Darunavir combination formulations
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
JP5843986B2 (ja) * 2014-03-25 2016-01-13 アステラス製薬株式会社 粒状医薬組成物
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
US10512633B2 (en) 2014-10-26 2019-12-24 King Abdullah University Of Science And Technology Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (HIV)
BR112020000842A2 (pt) 2017-07-20 2020-07-21 Janssen Sciences Ireland Unlimited Company composições e métodos para tratamento do hiv
WO2020064980A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of treating and preventing neuropsychiatric and/or neurocognitive complications in patients infected with hiv
WO2021180963A1 (en) 2020-03-13 2021-09-16 Janssen Sciences Ireland Unlimited Company A protease inhibitor regimen for treating subjects infected with hiv
JP7415045B2 (ja) * 2020-04-20 2024-01-16 ポビバ コーポレーション 抗ウイルス薬剤の向上した送達の為の組成物及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DK0715618T3 (da) 1993-08-24 1999-08-23 Searle & Co Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
AU2008267237A1 (en) * 2007-06-25 2008-12-31 Tibotec Pharmaceuticals Combination formulations comprising darunavir and etravirine
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
PL2477992T3 (pl) * 2009-09-17 2017-07-31 Mylan Laboratories Limited Proces przygotowania Darunawiru i jego amorficznych postaci

Similar Documents

Publication Publication Date Title
JP2011093937A5 (enExample)
JP2013539946A5 (enExample)
JP2014503786A5 (enExample)
JP2013531034A5 (enExample)
JP2013531018A5 (enExample)
JP2014026276A5 (enExample)
JP2014026275A5 (enExample)
JP2014026274A5 (enExample)
JP2012204203A5 (enExample)
JP2014505137A5 (enExample)
JP2015500269A5 (enExample)
JP2012031285A5 (enExample)
JP2013064178A5 (enExample)
JP2014189812A5 (enExample)
JP2014520787A5 (enExample)
JP2012193264A5 (enExample)
JP2012190699A5 (enExample)
JP2014531903A5 (enExample)
JP2016505534A5 (enExample)
JP2014520786A5 (enExample)
JP2011233516A5 (enExample)
JP2014534151A5 (enExample)
JP2014205658A5 (enExample)
JP2014005521A5 (enExample)
JP2013016377A5 (enExample)